CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(01): 085-098
DOI: 10.1055/s-0042-1749244
Presentation Abstracts

The First Steps of Lu-177-PSMA Therapy in Russia

Tatiana Kochetova
1   Department of Nuclear Therapy, MRRC, Russia
,
Valeriy Krylov
1   Department of Nuclear Therapy, MRRC, Russia
,
Andrey Kaprin
2   National Medical Research Radiological Centre of the Ministry of Health of the RF, Director, Russia
,
Sergey Ivanov
3   A.F.Tsyb Medical Radiological Research Center the branche of National Medical Research Radiological Centre of the Ministry of Health of the RF, Director, Russia
,
Karina Petrosyan
1   Department of Nuclear Therapy, MRRC, Russia
,
Andrey Shurinov
1   Department of Nuclear Therapy, MRRC, Russia
› Author Affiliations
› Further Information
 

  • Areas of Interest: Prostate

Background: The first case of the 177Lu-PSMA-617 induced remission was published in 2015 by Clemens Kratochwil from Heidelberg University Hospital. Since then, 177Lu-PSMA-617 castration resistant prostate cancer (CRPC) therapy has become widespread around the world. This year, the results of a phase-III randomized clinical study (VISION) were published confirming the positive effect of therapy on overall and progression-free survival. Based on the data from this study, the drug is likely to receive EMA and FDA approval. To date, 177Lu-PSMA-617 therapy has been an experimental method. For several years, Russian scientists have conducted preclinical studies of a domestic 177Lu-PSMA-617. The first administration of 177Lu-PSMA-617 to a CRPC patient was took place at the Medical Radiological Research Center in Russia on May 14, 2021.

Methods: Eight patients with high accumulation of PSMA according to PET-CT data received 177Lu-PSMA-617 therapy (from 2 to 8 GBq). Three of them started with concomitant Ra-223.

Results: According to the data of SPECT-CT and dynamic scintigraphy, 177Lu-PSMA-617 demonstrated predictable pharmacokinetics, high-absorbed doses in metastatic foci and low-absorbed doses in critical organs. The clinical results are a partial response or stable disease with a minimum number of side effects in the majority of patients.

Conclusion: Domestic 177Lu-PSMA-617 demonstrated promising results and it may take its rightful place among the methods of treatment resistant to other types of therapy of CRPC in the future.



Publication History

Article published online:
10 May 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India